Atticus Advisors

The pharmaceutical world is facing a disruptive shift, as former U.S. President Donald Trump signs an executive order aimed at slashing domestic drug prices. The crux of the move? A “most-favored-nation” pricing model—where American consumers would only pay what the lowest-priced developed country is paying for the same prescription drug. If enacted, this could reduce U.S. drug prices by as much as 30% to 80%, according to Trump.

In a move that surprised even the most seasoned global analysts, the United States and China stepped back from the edge of a worsening trade war during weekend talks in Geneva, Switzerland. With tariff threats mounting and both economies beginning to feel the bite, the two countries agreed to significantly roll back duties—for now.